Email This Article

Headlines & Perspectives
How Vytorin Fell Short
By Melissa Davis
01/22/08 - 10:58 AM EST
Merck and Schering-Plough took a risky path by launching an ill-fated trial for the cholesterol drug.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,187.72 1,085.91 2,147.18 34.46
Oil *
75.76
DOWN
103.54
DOWN
12.60
DOWN
19.72
DOWN
0.28
10 Yr
3.45%
SPDR Gold
108.37
-1.01%
-1.15%
-0.91%
-0.81%
Data delayed 20 minutes

Brokerage Partners